NCT01632150 - Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

March 31, 2016

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

BIOLOGICAL

Elotuzumab

Powder for solution, 400-mg vials, for infusion

BIOLOGICAL

Thalidomide

50-mg capsules administered orally

BIOLOGICAL

Dexamethasone

2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration

BIOLOGICAL

Cyclophosphamide

50-mg tablets administered orally

Trial Locations (10)

28034

Local Institution, Madrid

28041

Local Institution, Madrid

37007

Local Institution, Salamanca

38320

Local Institution, LaLaguna, S Cruz Tener

41013

Local Institution, Seville

50009

Local Institution, Zaragoza

08916

Local Institution, Barcelona

08035

Local Institution, Barcelona

08036

Local Institution, Barcelona

08041

Local Institution, Barcelona